11.08.2016
Biotest AG DE0005227235
DGAP-News: Biotest AG: Biotest increases EBIT significantly
DGAP-News: Biotest AG / Key word(s): Half Year Results
Biotest AG: Biotest increases EBIT significantly
11.08.2016 / 10:01
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
PRESS RELEASE
Biotest increases EBIT significantly
- Strong EBIT increase to EUR 18.2 million vs. EUR 2.3 million
- Increase of revenue by 6.4% to EUR 306 million
- Operating Cash flow increased to EUR 50 million
Dreieich, 11 August 2016. In the first half of 2016 the Biotest Group
recorded revenue of EUR 306.1 million, representing an increase of 6.4%
compared to the same period of the previous year (EUR 287.7 million). The
markets of North America as well as Middle East and Africa made the most
significant contribution to the revenue growth. However, the company
achieved the highest growth rates year-on-year in the Central and South
America region.
Despite higher expenses for the development of new products and the
expansion of the production facility within the "Biotest Next Level"
project in the amount of EUR 17 million, the EBIT increased considerably
from EUR 2.3 million to EUR 18.2 million. A higher gross profit, a better
utilization of the US facility and significantly reduced expenses for the
monoclonal antibodies were the main drivers for the EBIT increase. The
operating cash flow increased by 59.0% to EUR 49.6 million vs. EUR 31.2
million in the previous year period.
This resulted in earnings before taxes (EBT) of EUR 13.9 million for the
Biotest Group compared to EUR 2.1 million in the same period of the
previous year. Earnings after taxes (EAT) amounted to EUR 7.7 million (same
period of the previous year: EUR -2.2 million). Earnings per share thus
increased from EUR -0.05 to EUR +0.19 in the period under review.
Outlook:
The Board of Management confirms the guidance of an increase in sales in
the low single-digit percentage range and an EBIT in the range of EUR 33 to
35 million for 2016.
The half-year report can be downloaded from Biotest's website: http://
www.biotest.de/ww/en/pub/investor_relations/publications/
quarterly_reports.cfm
About Biotest
Biotest is a provider of plasma proteins and biological drugs. With a value
added chain that extends from pre-clinical and clinical development to
worldwide sales, Biotest has specialised primarily in the areas of clinical
immunology, haematology and intensive medicine. Biotest develops and
markets immunoglobulins, coagulation factors and albumins based on human
blood plasma. These are used for diseases of the immune and haematopoietic
systems. In addition Biotest develops monoclonal antibodies in the
indications of cancer of plasma cells and systemic lupus erythematosus
which are produced by recombinant technologies. Biotest has more than 2,300
employees worldwide. The preference shares of Biotest AG are listed in the
SDAX on the Frankfurt stock exchange.
IR contact
Dr. Monika Buttkereit
phone: +49-6103-801-4406
email: [email protected]
PR contact
Dirk Neumüller
phone: +49-6103-801-269
email: [email protected]
Biotest AG, Landsteinerstr. 5, 63303 Dreieich, www.biotest.de
Ordinary shares: securities' ID No. 522720; ISIN DE0005227201
Preference shares: securities' ID No. 522723; ISIN DE0005227235
Listing: Prime Standard
Open Market: Berlin, Düsseldorf, Frankfurt, Hamburg, Hannover, Munich,
Stuttgart
Disclaimer
This document contains forward-looking statements on overall economic
development as well as on the business, earnings, financial and assets
position of Biotest AG and its subsidiaries. These statements are based on
current plans, estimates, forecasts and expectations of the company and are
thus subject to risks and elements of uncertainty that could result in
significant deviation of actual developments from expected developments.
The forward-looking statements are only valid at the time of publication.
Biotest does not intend to update the forward-looking statements and
assumes no obligation to do so.
---------------------------------------------------------------------------
11.08.2016 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Biotest AG
Landsteinerstraße 5
63303 Dreieich
Germany
Phone: 0 61 03 - 8 01-0
Fax: 0 61 03 - 8 01-150
E-mail: [email protected]
Internet: http://www.biotest.de
ISIN: DE0005227235, DE0005227201
WKN: 522723, 522720
Indices: SDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover,
Munich, Stuttgart, Tradegate Exchange
End of News DGAP News Service
---------------------------------------------------------------------------
491639 11.08.2016
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
Biotest AG ISIN: DE0005227235 können Sie bei EQS abrufen
Gesundheit , 522723 , BIO3 , XETR:BIO3